DexCom

216 articles with DexCom

• Dexcom Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for February 21, 2019 at 4:30 p.m. Eastern Time

  1/24/2019

  DexCom (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2018 financial results after market close on Thursday, February 21, 2019.

• Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2018 and Provides Initial 2019 Outlook

  1/7/2019

  For fiscal 2018, total preliminary, unaudited revenue is expected to exceed $1.025 billion, an increase of more than 42% over 2017.

• Dexcom Announces Upcoming January 2019 Conference Presentation

  12/18/2018

  DexCom, Inc. today announced that management will present an update on Dexcom at the following upcoming investor conference

• Dexcom Donates $25,000 to Beyond Type 1

  12/11/2018

  Social media campaign #NoMoreFingerpricks raises funds and awareness for diabetes research

• DexCom Prices Offering of $750.0 Million of 0.75% Convertible Senior Notes

  11/28/2018

  DexCom, Inc. announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended

• DexCom Announces Proposed Offering of $750 Million of Convertible Senior Notes

  11/26/2018

  DexCom, Inc. announced today that it intends to offer, subject to market conditions and other factors, $750 million aggregate principal amount of Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

• Dexcom to Host Investor Day on December 4, 2018

  11/7/2018

  DexCom, Inc. today announced that it will host an Investor Day on December 4, 2018 at the Laguna Cliffs Marriott in Dana Point, California. The event will include updates on the company’s innovation pipeline, business strategy, and long-term financial outlook.

• Dexcom G6® Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries with Diabetes in Early 2019

  10/18/2018

  CMS approves coverage for Dexcom G6 CGM, the only CGM system recognized by Medicare that offers mobile device compatibility and no fingerstick calibration

• Validic Announces Partnership With DexCom To Allow For CGM Data Access, Comprehensive Patient Care

  10/17/2018

  Dexcom CGM data from Dexcom's cloud API is integrated into the Validic data connectivity platform – establishing one of the first multi-measure platforms to stream in-home clinical data directly into clinical workflows and systems.

• DexCom Schedules Third Quarter 2018 Earnings Release and Conference Call for November 6, 2018 at 4:30 p.m. Eastern Time.

  10/8/2018

  DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2018 financial results after market close on Tuesday, November 6, 2018.

• DexCom Announces Upcoming Conference Presentation on September 12, 2018

  8/22/2018

  DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference:

• DexCom Reports Second Quarter 2018 Financial Results

  8/1/2018

  DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended June 30, 2018.

• DexCom Announces Upcoming Conference Presentation---

  7/25/2018

  DexCom, Inc. today announced that management will present an update on DexCom at the following upcoming investor conference.

• DexCom Schedules Second Quarter 2018 Earnings Release and Conference Call for August 1, 2018 at 4:30 p.m. Eastern Time.

  7/3/2018

  DexCom, Inc. today announced that it plans to release its second quarter 2018 financial results after market close on Wednesday, August 1, 2018.

• Dexcom G6® CGM System Receives CE Mark

  6/12/2018

  Revolutionary new CGM system eliminates routine fingersticks for people with diabetes and is nearly one-third smaller than previous generation

• Dexcom G5 Continuous Glucose Monitoring System Now Available on Mobile, Smart Devices for Medicare Patients with Diabetes

  6/11/2018

  Dexcom, Inc. announced the U.S. Centers for Medicare & Medicaid Services (CMS) is updating its policy on mobile device compatibility for the Dexcom G5® CGM System.

• Federal Court Judge Awards AgaMatrix Attorneys' Fees While Admonishing Dexcom for "Bad Faith" Lawsuit

  6/5/2018

  AgaMatrix, Inc. announced a prevailing outcome in a retaliatory patent infringement lawsuit brought by Dexcom, Inc. (NASDAQ: DXCM).

• DexCom Reports First Quarter 2018 Financial Results

  5/2/2018

  DexCom, Inc. reported its unaudited financial results as of and for the quarter ended March 31, 2018.

• FDA Authorizes Marketing of the New Dexcom G6® CGM Eliminating Need for Fingerstick Blood Testing for People with Diabetes

  3/27/2018

  DexCom, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up.

• FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices

  3/27/2018

  The U.S. Food and Drug Administration today permitted marketing of the DexCom G6 integrated continuous glucose monitoring (iCGM) system for determining blood glucose (sugar) levels in children aged two and older and adults with diabetes.